HUTCHMED (NASDAQ:HCM) Shares Gap Up – What’s Next?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $14.95, but opened at $15.42. HUTCHMED shares last traded at $15.75, with a volume of 9,897 shares trading hands.

HUTCHMED Trading Down 0.3 %

The firm’s fifty day moving average price is $14.69 and its 200 day moving average price is $16.52. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On HUTCHMED

A number of large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in HUTCHMED during the 3rd quarter worth $35,000. Barclays PLC boosted its stake in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after purchasing an additional 2,255 shares during the period. Blue Trust Inc. boosted its stake in HUTCHMED by 99.9% during the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares during the period. Summit Trail Advisors LLC boosted its stake in HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after purchasing an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC acquired a new stake in HUTCHMED during the 4th quarter worth $230,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.